Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Bini (Milano (Mi), Italy), D. Visca (Tradate (Va), Italy), A. De Lauretis (Milano (Mi), Italy), B. Bodini (Milano (Mi), Italy), D. Colombo (Milano (Mi), Italy), P. Faverio (Monza, Italy), A. Vaghi (Monza, Italy). Use of Rituximab in the treatment of CTD-ILD in RA patients.. 1817

Member's Comments

No comment yet.

Related content which might interest you: Use of a protocol to select patients for omalizumab treatment Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Long-term treatment with infliximab in patients with sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis Source: Eur Respir J 2002; 20: Suppl. 38, 587s Year: 2002 Rituximab in the treatment of refractory pulmonary sarcoidosis Source: Eur Respir J 2014; 43: 1525-1528 Year: 2014 Rituximab improves interstitial lung disease in rheumatoid arthritis patients Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 High-doses glucocorticosteroid treatment in sarcoidosis patients Source: Eur Respir J 2007; 30: Suppl. 51, 118s Year: 2007 Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Pulmonary non-Hodgkin‘s lymphoma developed during long-term methotrexate therapy for rheumatoid arthritis Source: Annual Congress 2009 - Various diagnostic aspects in lung cancer and rare lung tumours Year: 2009 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Glucocorticosteroid treatment in sarcoidosis: comparison of regimens Source: Eur Respir J 2003; 22: Suppl. 45, 234s Year: 2003 Use of surfactant-BL (S-BL) in complex treatment of pulmonary TB patients Source: Eur Respir J 2003; 22: Suppl. 45, 521s Year: 2003 Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab Source: International Congress 2016 – Sarcoidosis Year: 2016 Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis Source: Eur Respir J 2004; 24 : 708 Year: 2004 Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Real-world treatment patterns of benralizumab therapy for patients with severe asthma Source: Virtual Congress 2020 – Diagnosis and management of asthma Year: 2020 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 The response to combination therapy treatment regimens in severe/difficult-to-treat asthma Source: Eur Respir J 2008; 32: 1237-1242 Year: 2008